Related references
Note: Only part of the references are listed.A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease
Shweta Shah et al.
LEUKEMIA & LYMPHOMA (2020)
Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
Cosimo Cumbo et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Emerging therapies in mantle cell lymphoma
Walter Hanel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
Remy Gressin et al.
HAEMATOLOGICA (2019)
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2019)
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma
Pavel Klener et al.
HEMATOLOGICAL ONCOLOGY (2018)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Felicitas Thol et al.
BLOOD (2018)
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
Pavel Klener et al.
HEMATOLOGICAL ONCOLOGY (2018)
[11C]Methionine emerges as a new biomarker for tracking active myeloma lesions
Constantin Lapa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
Carlo Visco et al.
LANCET HAEMATOLOGY (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
Julie M. Vose
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Arne Kolstad et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
Andrew J. Cowan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
O. Landgren et al.
BONE MARROW TRANSPLANTATION (2016)
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
Philippe Armand et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment
Eva Hoster et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
Juliana Maria Camargos Rocha et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)
Mantle cell lymphoma: evolving management strategies
Elias Campo et al.
BLOOD (2015)
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Arne Kolstad et al.
BLOOD (2014)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucemies et Autres Maladies du Sang
Estelle Gimenez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
Hongtao Liu et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
How to obtain the confidence interval from a P value
Douglas G. Altman et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
Christiane Pott et al.
BLOOD (2010)
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
Niels S. Andersen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia:: results from the GCLLSG CLL3X trial
M. Ritgen et al.
LEUKEMIA (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
C Pott et al.
BLOOD (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy
AC Rawstron et al.
BLOOD (2001)
Share Paper
